Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multicenter, Phase I Trial of the Safety and Pharmacokinetics of Escalating Doses of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma

NCT01432353 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT01432353
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01432353 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multicenter, Phase I Trial of the Safety and Pharmacokinetics of Escalating Doses of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma
Lead sponsor
Genentech, Inc.
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2011
Completion date
April 30, 2014
Enrollment
39 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma